The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.

Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

A new study links abdominal fat, especially in women, to increased risk of psoriasis, regardless of genetic predisposition, ...

Secukinumab, an anti-IL-17A monoclonal antibody biologic drug, showed promise as a treatment for patients with active ankylosing spondylitis, according to new research. Ankylosing spondylitis, or ...

Secukinumab treatment reduces bone erosion volume and enhances partial healing of erosions in patients with psoriatic arthritis, according to results from a randomized controlled trial.

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1Safety in GCA patients was consistent with known safety profile o ...

The interplay between Th1 and Th17 immune pathways sustains inflammation in both GPP and SLE, supporting IL-17 inhibition as an effective therapy for these conditions when concurrent.

Hidradenitis suppurativa is a chronic, systemic, and often painful skin condition. Here’s what it’s like living with it.

Researchers identified the association between single nucleotide polymorphisms and clinical response to secukinumab in patients with plaque psoriasis.